Hastings Gregory S has reported recent transactions involving shares and restricted stock units of Neogen Corp, a company in the in vitro and in vivo diagnostic substances sector. This update is significant as it reflects ongoing investment activity that could influence market perceptions and strategies within the industry.

Hastings Gregory S is an officer at Neogen Corp, which is listed under the ticker symbol NEOG. The company operates within the diagnostic substances sector, focusing on in vitro and in vivo diagnostics. According to recent filings, Hastings has made multiple transactions recently, indicating active management of his stock holdings.

The filing reveals that on October 29, 2026, Hastings acquired 1,211 shares of Neogen common stock at a price of $12.21 per share. Additionally, he disposed of 337 shares under a different transaction code, maintaining a total of 33,449 shares following these transactions. The filing also notes that Hastings exercised restricted stock units, which vested on the same date, resulting in the acquisition of an equivalent number of shares.

These transactions may affect various stakeholders, including investors and other officers within Neogen Corp. The increase in share ownership by Hastings could be viewed as a positive signal about the company's future, potentially influencing investor confidence.

The filing does not say what happens next regarding further transactions or strategic plans.